

# 2014 Analysis of the UK Hospital Tumor Marker Testing Market

https://marketpublishers.com/r/213E0EABF94EN.html

Date: November 2013 Pages: 527 Price: US\$ 3,080.00 (Single User License) ID: 213E0EABF94EN

### Abstracts

This new report from Venture Planning Group contains 527 pages, 37 tables and presents a comprehensive analysis of the UK hospital tumor marker testing market, including:

Major issues pertaining to the UK hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e. g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in UK hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.



Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 527 pages and 37 tables



### Contents

#### INTRODUCTION

#### WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
  - 1. Breast Cancer
  - 2. Lung Cancer
  - 3. Colon and Rectum Cancer
  - 4. Prostate Cancer
  - 5. Stomach Cancer
  - 6. Leukemia
  - 7. Lymphoma
  - 8. Oral Cancer
  - 9. Skin Cancer
  - 10. Uterine Cancer
  - 11. Ovarian Cancer
  - 12. Bladder Cancer
- B. Major Current And Emerging Cancer Diagnostic Tests
  - 1. Introduction
  - 2. Tumor Marker Classification
  - 3. ACTH
  - 4. Alpha-Fetoprotein (AFP)
  - 5. Beta-2 Microglobulin
  - 6. CA 15-3/27. 29
  - 7. CA 19-9
  - 8. CA-125
  - 9. Calcitonin
  - 10. Carcinoembrionic Antigen (CEA)
  - 11. Estrogen and Progesterone Receptors
  - 12. Ferritin
  - 13. Gastrin
  - 14. Human Chorionic Gonadotropin (HCG)
  - 15. Insulin
  - 16. NSE
  - 17. Occult Blood
  - 18. PAP Smear/HPV
  - 19. Prostatic Acid Phosphatase (PAP)



20. Prostate-Specific Antigen (PSA) 21. Squamous Cell Carcinoma Antigen (SCC) 22. T and B Lymphocytes 23. TdT 24. Thyroglobulin 25. Tissue Polypeptide Antigen (TPA) 26. Biochemical Tumor Markers ADA **B-Protein** PNP 5'-Nucleotidase 27. Oncogenes Abl/abl-bcr AIB1 BCL-2 BRCA1 **CD44** C-fos C-myb C-myc **CYP-17** Erb-B HPC1 N-myc P40 P51 P53 PIK3CA PTI-1 Ras Reg Sis Src 28. Polypeptide Growth Factors **Basic Fibroblast Growth Factor Beta-TGF** Cachectin (TNT) Calmodulin



Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors 31. Lymphokines Alpha-Interferon **B Cell Growth Factors B** Cell Growth Factor (BCGF) Gamma-Interferon Interleukin-1 (IL-1) Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Tumor Markers N-Acetylglucosamine Actin Alpha-Actin **Antineuronal Antibodies** 7B2 B72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA 50 CA 72-4/TAG-72 CA 195 CA-242 CA-549 **CAM 26** CAR-3 Cathepsin-D Chromogranin A and B Cluster 1 Antigen Cluster-5/5A Antigen CTA

CU18



**DR-70** DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH (1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15 Glucagon Glycoamines H23 Her-2 Human Carcinoma Antigen **HPA** HSP27 **Intermediate Filaments** Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein Neurofilaments** Vimentin KA 93 **Kinases KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma 552 MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA)



Multiple Tumor Suppressor 1 Myosin **NEA-130** NMP22 OA-519 **Opiod Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA) **Placental Lactogen PR92** Proliferative Index, Ki-67 Px **RB** Inactivation/Deletion Ret **SCCL 175** Selectin Sialic Acid Sialyl SSEA-1/SLX **SN10** Somatostatin **TA-90** TABA Tachykinin **TAG 12** TPS Troponin Tubulin VCAM VEGF Villen C. Instrumentation Review And Market Needs 1. Abbott AxSYM

- 2. Abbott Architect c4000
- 3. Abbott Architect i2000 Series
- 4. Abbott Architect ci8200 System
- 5. Beckman Coulter UniCel Series
- 6. Beckman Coulter Access
- 7. Binding Site ESP600
- 8. bioMerieux Mini Vidas



- 9. Carolina Chemistries BioLis 24i
- 10. DiaSorin Liaison
- 11. Horiba ABX Pentra 400
- 12. Inverness DS2
- 13. J&J Vitros ECi/ECiQ
- 14. J&J Vitros 3600
- 15. J&J Vitros 5600
- 16. Olympus AU5400
- 17. Olympus AU3000i
- 18. Olympus AU2700
- 19. Roche Modular Analytics
- 20. Roche Cobas Integra 400
- 21. Roche Cobas Integra 400 Plus
- 22. Roche Elecsys
- 23. Roche Cobas c311
- 24. Siemens ADVIA Centaur
- 25. Siemens Dimension
- 26. Siemens Dimension RxL Max
- 27. Siemens Dimension Vista 500
- 28. Siemens Immulite
- 29. Siemens Stratus
- 30. Tosoh AIA-Series
- 31. Vital Diagnostics ATAC 8000
- 32. Vital Diagnostics Envoy 500
- D. Current and Emerging Technologies
  - 1. Monoclonal and Polyclonal Antibodies
  - 2. Immunoassays
    - a. Technological Principle
    - b. Radioimmunoassay (RIA)
    - c. Enzyme Immunoassays (EIA)
    - Overview

**ELISA** 

Immunofiltration

Particle-Membrane Capture Immunoassay

- **Enzyme Amplification**
- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence

Bioluminescence



- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- e. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
- a. Technology Overview
- b. Amplification Methods
  - PCR
  - DAP-PCR
  - Immuno-PCR
  - QC-PCR
  - CAR
  - DNA
  - HPA
  - LCR
  - NASBA
  - QBR
  - SDA
  - 3 SR, and others
- 4. Chromosome Analysis
  - a. Chronic Myelogenous Leukemia (CML)
  - b. Acute Myeloid Leukemia (AML)
  - c. Acute Lymphoblastic Leukemia (ALL)
  - d. Malignant Lymphomas Lymphoid Malignancies
  - e. Chronic Lymphocytic Leukemia (CLL)
  - f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
- a. CT
- b. MRI
- c. NMR
- d. PET
- e. Photonics Spectroscopy
- E. Personal Testing



#### U. K.

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

#### MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- **D.** Auxiliary Products

#### DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

#### ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
  - 1. Marketing Approaches
  - 2. Product Complexity
  - 3. Customer Preference
  - 4. Established Suppliers
  - 5. Emerging Suppliers
  - 6. Major Types of Distributors
  - 7. Market Segmentation Factor

#### POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges



#### **COMPETITIVE PROFILES**

Abbott AdnaGen Applied Gene Technologies Arca Beckman Coulter/Danaher **Becton Dickinson Biomedical Diagnostics bioMerieux Bio-Rad** Cepheid **Correlogic Systems** Dako Decode Diadexus Diagnocure Diasorin **Eiken Chemical** Enterix Enzo Biochem **Epigenomics Exact Sciences** Fujirebio Gen-Probe **Guided Therapeutics** Hologic Ipsogen **Kreatech** Kyowa Medex Life Technologies Mackay Life Sciences Myriad Genetics Nanogen Elitech OncoLab **Otho-Clinical Diagnostics** Panacea Pharmaceuticals **Polartechnics** Polymedco



PreMD Qiagen Radient Pharmaceuticals Roche Scienion Sequenom Siemens Healthcare Takara Bio Targeted Diagnostics & Therapeutics Tosoh Veridex Wako Pure Chemicals Wallac/PE Zila

#### **APPENDIXES**

#### APPENDIX I: MAJOR UNIVERSITIES AND RESEARCH

**CENTERS DEVELOPING CANCER DIAGNOSTIC** 

#### **TECHNOLOGY AND APPLICATIONS**

#### **APPENDIX II: ASSUMED CURRENCY EXCHANGE RATES**



## **List Of Tables**

#### LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27. 29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests **Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer** Diagnosis Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer **Diagnosis Lymphokines Potential Applications In Cancer** Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis Executive Summary Table: U. K., Hospital Cancer Diagnostic Test Volume and Sales Forecast by Market Segment U. K., Estimated Cancer Death Rates Per 100,000 Population U. K., Hospital Laboratories Performing Cancer Diagnostic Tests U. K., Hospital Laboratories Performing Cancer Diagnostic Tests by Bed Size U. K., Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast By Test

- U. K., Hospital Laboratories Cancer Diagnostics Sales Forecast by Test
- U. K., Total Cancer Diagnostics Sales By Major Supplier



U. K., CEA Testing Market Diagnostics Sales by Major Supplier U. K., PSA Testing Market Diagnostics Sales by Major Supplier



#### I would like to order

Product name: 2014 Analysis of the UK Hospital Tumor Marker Testing Market Product link: <u>https://marketpublishers.com/r/213E0EABF94EN.html</u>

> Price: US\$ 3,080.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/213E0EABF94EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970